Abstract
Introduction:PURA syndrome is a neurodevelopmental disease caused by de novo pathogenic variants in PURA encoding the purine-binding element alpha protein. It is characterized by autosomal dominant inheritance and a heterogeneous phenotype. Case Presentation: We describe a 7-year-old patient with history of congenital pneumonia, accompanied by hypotonia, convulsive episodes, poor sucking ability, neurodevelopmental delay. Physical examination revealed some dysmorphic features. Molecular analysis identified a de novo, heterozygous variant in PURA (NM_005859.5): c.692T>C; p.Phe231Ser, which was classified as pathogenic. Conclusion: In this report, we present a Colombian case of PURA syndrome. This case highlights the challenges associated with the early diagnosis of a newly described syndrome, in a limited-resources health system.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Shimojima
K
, Isidor
B
, Le Caignec
C
, Kondo
A
, Sakata
S
, Ohno
K
, et al. A new microdeletion syndrome of 5q31.3 characterized by severe developmental delays, distinctive facial features, and delayed myelination
. Am J Med Genet A
. 2011
;155A
(4
):732
–6
. 2.
Reijnders
MRF
, Janowski
R
, Alvi
M
, Self
JE
, van Essen
TJ
, Vreeburg
M
, et al. PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature
. J Med Genet
. 2018
;55
(2
):104
–13
. 3.
Johannesen
KM
, Gardella
E
, Gjerulfsen
CE
, Bayat
A
, Rouhl
RPW
, Reijnders
M
, et al. PURA- related developmental and epileptic encephalopathy: phenotypic and genotypic spectrum
. Neurol Genet
. 2021
;7
(6
):e613
. 4.
Lalani
SR
, Zhang
J
, Schaaf
CP
, Brown
CW
, Magoulas
P
, Tsai
ACH
, et al. Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome
. Am J Hum Genet
. 2014
;95
(5
):579
–83
. 5.
Hunt
D
, Leventer
RJ
, Simons
C
, Taft
R
, Swoboda
KJ
, Gawne-Cain
M
, et al. Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability
. J Med Genet
. 2014
;51
(12
):806
–13
. 6.
Liu
Y
, Liu
R
, Xu
T
, Zhou
YX
, Zhang
SC
. Neonatal PURA syndrome: a case report and literature review
. Transl Pediatr
. 2021
;10
(1
):194
–203
. 7.
Tanaka
AJ
, Bai
R
, Cho
MT
, Anyane-Yeboa
K
, Ahimaz
P
, Wilson
AL
, et al. De novo mutations in PURA are associated with hypotonia and developmental delay
. Cold Spring Harb Mol Case Stud
. 2015
;1
(1
):a000356
. 8.
Kanai
Y
, Dohmae
N
, Hirokawa
N
. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule
. Neuron
. 2004
;43
(4
):513
–25
. 9.
Dobretsova
A
, Johnson
JW
, Jones
RC
, Edmondson
RD
, Wight
PA
. Proteomic analysis of nuclear factors binding to an intronic enhancer in the myelin proteolipid protein gene
. J Neurochem
. 2008
;105
(5
):1979
–95
. 10.
Kobayashi
Y
, Tohyama
J
, Kato
M
, Akasaka
N
, Magara
S
, Kawashima
H
, et al. High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders
. Brain Dev
. 2016
;38
(3
):285
–92
. 11.
Manickam
K
, McClain
MR
, Demmer
LA
, Biswas
S
, Kearney
HM
, Malinowski
J
, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)
. Genet Med
. 2021
;23
(11
):2029
–37
. 12.
Richards
S
, Aziz
N
, Bale
S
, Bick
D
, Das
S
, Gastier-Foster
J
, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and Genomics and the association for molecular pathology
. Genet Med
. 2015
;17
(5
):405
–24
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
